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Abstract Adverse food reactions are far more often
perceived than objectively verified. In our scientific
knowledge on non-allergic adverse reactions includ-
ing the so called histamine intolerance, there are large
deficits. Due to the fact that this disorder is increas-
ingly discussed in the media and the internet, more
and more people suspect it to be the trigger of their
symptoms. The scientific evidence to support the pos-
tulated link between ingestion of histamine and ad-
verse reactions is limited, and a reliable laboratory
test for objective diagnosis is lacking. This position
paper by the “Food Allergy”Working Group of the Ger-
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Background and objectives of the guideline
Adverse reactions are more often subjectively per-
ceived than objectively verifiable. There are large
deficits particularly in our scientific knowledge on
non-allergic adverse reactions. Histamine intoler-
ance is an example in point: due to the fact that it is
increasingly discussed in the media and Internet, sub-
jectively affected individuals often suspect it to be the
trigger of their symptoms. The scientific evidence to
support this postulated link is limited, and a reliable
laboratory test for the purpose of conclusive diagno-
sis is lacking. Although scientific studies on adverse
reactions to ingested histamine have been carried out
predominantly in adults to date, the diagnosis is also
made in children and adolescents, often with signifi-
cant consequences to the diets of affected individuals.
Two reports on digestive disorders in children caused
by histamine are now available [1, 2]. A retrospective
observational study conducted in Spain [1] discusses
histamine as a possible trigger; however, since di-
agnosis was based on low diamine oxidase (DAO)
levels and dietary modifications without follow-up
challenge, this study was not in line with recommen-
dations. A German study [2] concluded that, although
50% of patients with suspected histamine intolerance
responded to dietary changes, double-blind, placebo-
controlled provocation was able to prove only one
case of histamine intolerance.
This position paper by the “Food Allergy” Work-
ing Group of the German Society for Allergology and
Clinical Immunology (DGAKI) in collaboration with
the German Association of Allergologists (AeDA), the
Society for Pediatric Allergology and Environmental
Medicine (GPA), and the Swiss Society for Allergol-
ogy and Immunology (SGAI) reviews the data on the
clinical picture of adverse reactions to ingested his-
tamine, summarizes important aspects and their con-
sequences, and proposes a practical diagnostic and
therapeutic approach.
Ingested histamine is often suspected as the cause
of (unspecific) symptoms, despite the fact that the
scientific data supporting a clinical picture of this
type is limited.
Fig. 1 Histaminedegradationpathways
Occurrence, function, and degradation pathways
of histamine
Histamine is a biogenic amine derived from the de-
carboxylation of the amino acid histidine. Endoge-
nously synthesized histamine, which is stored primar-
ily in mast cells and basophils, is one of the most im-
portant mediators not only of IgE-, but also of non-
IgE-dependent clinical reactions. The body metabo-
lizes histamine via two known degradation pathways
(Fig. 1):
● Methylation by histamine-N-methyltransferase
(HNMT),
● Oxidative degradation by diamine oxidase (DAO).
Ingested histamine also needs to be metabolized
via these degradation pathways. Large quantities
can cause poisoning: histamine quantities above
100 milligrams (mg) can elicit mild, quantities above
1000mg severe intoxication. Histamine intoxication
most commonly occurs following the consumption of
spoiled fish, particularly from the family Scombridae
(tuna, mackerel, etc.).
Diagnostic work-up for adverse reactions to in-
gested histamine
There is no reliable procedure as yet for the diagnosis
of adverse reactions to ingested histamine. Since it
is most often self-diagnosed by the patient or solely
based on patient history, it is helpful to examine rele-
vant aspects more closely in order to answer the fol-
lowing questions: Which symptoms can be expected
and which differential diagnosis could be helpful? Is
there evidence of the presumed pathomechanism?
Which parameters are described for the diagnostic
work-up and how reliable are they? Can drug therapy
influence the disease pattern? The confirmation of
the suspected diagnosis by oral provocation is also
discussed, as are the difficulties that arise due to vari-
able levels in foods. An explanation of terms rounds
up the data discussed here.
Symptoms and differential diagnoses in patients
with suspected adverse reactions to ingested
histamine
The spectrumof symptoms in the so called “histamine
intolerance” can affect several organ systems and is
complex. Classic symptoms include sudden facial ery-
thema (flushing), pruritus, and rashes on the body.
Histamine can also cause gastrointestinal symptoms,
such as nausea and/or vomiting/diarrhea and abdom-
inal pain. Symptoms related to the respiratory tract,
as well as cardiovascular symptoms such as low blood
pressure, dizziness, or tachycardia, are rarer but not
unknown [3–5].
Given the extensiveness of clinical symptoms, it
is important to make a broad differential diagnosis
covering skin disorders such as urticaria, as well as
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Table 1 Symptomsanddifferential diagnoses inpatientswith suspectedadverse reactions to ingestedhistamine
Symptoms Differential diagnosis(es)
Flushinga Neuroendocrine tumors
Itchinga Urticaria, pruritus sine materia, prurigo
Nausea/vomitinga Gastric ulcer, duodenal ulcer
Diarrhea and abdominal paina Chronic inflammatory bowel disorders, carbohydrate metabolism disorders
(lactose intolerance, fructose malabsorption), celiac disease
Rhinitisa Allergic and non-allergic rhinitis
Dyspnea, dysphoniaa Allergic and non-allergic asthma
Low blood pressure, dizziness, tachycardiaa Anaphylaxis
aAnalyzing symptoms with reference to their temporal onset provides important differential diagnostic information; adverse food reactions are only suspected in
the case of a temporal relationship (min <4 h) to food intake
chronic inflammatory gastrointestinal disorders, car-
bohydrate metabolism disorders, celiac disease, and
other allergic diseases (Table 1).
Presumed pathomechanism
Since the mid 1980s, ingested biogenic amines have
been suspected of causing adverse reactions in some
individuals even in small quantities, which are be-
low the toxic dose. The discussion has focussed on
adverse reactions elicited by histamine-containing
foods, despite the fact that other biogenic amines
(cadaverine, tryptamine, tyramine, serotonin, etc.)
and/or polyamines (putrescine, spermine, spermi-
dine, among others) also cause adverse reactions
or may affect histamine metabolism [6]. The sus-
pected pathomechanism for reactions to ingested
histamine involves impaired degradation by catab-
olizing enzymes, primarily DAO [4]. The term “his-
tamine intolerance” was coined with reference to
the term “lactose intolerance” (due to enzyme de-
ficiency). However, prospective controlled studies
conclusively demonstrating that an enzyme and/or
deficient enzyme activity is/are the cause of reactions
to ingested histamine are lacking to date. It must be
borne in mind that histamine can be degraded via
two pathways (Fig. 1).
Impaired histamine catabolism due to diamine
oxidase deficiency is postulated as the cause of
adverse reactions to ingested histamine; this causal
link, however, has yet to be proven.
The described diagnostic parameters and their
reliability
A number of different parameters have been proposed
for the diagnosis of “histamine intolerance”; these are
discussed below with regard to their reliability.
DAO activity in serum
According to current data, diagnosis based on the
measurement of DAO enzyme activity in blood serum
cannot be considered conclusive [7, 8]. Using DAO-
specific monoclonal antibodies, it was possible to de-
tect DAO in various tissues, such as kidneys, intestine,
and placenta—not, however, in blood serum, or at
least not in relevant quantities [9]. This finding casts
conclusive doubt on the utility of serum analysis.
Nevertheless, a recent study has once again pro-
claimed the reliability of determining DAO activity in
blood serum [10]. In stark contrast to earlier works
[7, 8], DAO values in that particular study’s limited
control group were in the normal range.
Histamine 50-skin-prick test
Meanwhile, Kofler and coworkers have published
a study that could indeed support slowed histamine
degradation [11]. As part of the so-called histamine
50-prick-test, the histamine wheal was re-read after
50min. If wheal size remained unaltered up to that
time, impaired degradation was assumed. However,
this method does not permit conclusions to be drawn
on whether the degradation of ingested histamine is
slowed down and needs to be viewed highly critically.
Measurement of intestinal enzyme activity
Potential diagnostic significance is attributed to the
measurement of enzyme activity (or activities) (DAO
and possibly HNMT) in the intestinal mucosa, since
this is considered the most important organ for the
degradation of histamine from exogenous sources.
However, according to current knowledge, blood DAO
levels in humans—in contrast to animals—do not per-
mit any conclusions to be drawn on enzyme activity
of DAO in the small intestine [12].
Further scientific investigation is needed to estab-
lish whether the determination of DAO activity in the
small intestinal mucosa yields information on the ca-
pacity to degrade exogenous histamine.
Kuefner and coworkers demonstrated a trend to-
ward reduced DAO activity in the colonic mucosa of
patients with food allergies, but without reaching sig-
nificance levels [13]. HNMT activity, on the other
hand, was markedly diminished; parallel to this, his-
tamine values in the intestinal mucosa were elevated.
The authors see this diminished HNMT activity as the
primary cause of impaired histamine metabolism in
the colon. However, the study did not investigate the
effect of ingested histamine.
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The same working group showed that not only DAO
activity, but also to a greater extent HNMT activity
was likewise diminished in damaged tissue in colonic
adenoma patients [14]. The authors found slightly
increased histamine concentrations in bowel tissue;
however, this did not correlate with enzyme activity.
They concluded that the histamine in the colonic mu-
cosa was more likely to be elevated due to increased
release rather than reduced degradation. The effect of
exogenous histamine intake was not investigated.
Histamine in the intestine is degraded not only by
diamine oxidase, but possibly also by histamine
N-methyl-transferase.
Histamine in stool samples
It is now known that some bacteria of the intestinal
microbiota, in particular lactobacilli, partially secrete
large quantities of histamine. This casts doubt on
the validity of high histamine levels in stool samples
as pathological. O’Mahony and his working group
showed in a mouse model that histamine produced in
the intestinal lumen—depending on which histamine
receptor (HR) it binds to—not only has proinflamma-
tory, but also regulatory effects on the immune sys-
tem. If the secreted histamine binds to the histamine
H2 receptor (H2R), it has more of a regulatory effect
[15–17].
The fact that histamine is a relevant metabolite of
intestinal bacteria casts doubt on the validity of
diagnostic stool analysis.
Histamine levels in plasma
The significance of determining plasma histamine
levels is subject to scientific controversy. Giera and
coworkers performed provocation tests in patients
with suspected histamine intolerance and controls
with 75mg histamine and placebo [18]. The rise in
plasma histamine following verum administration
was minimal in patients with suspected histamine
intolerance and did not differ from the control group,
not even in those patients that exhibited symptoms
in response to provocation. In the control group, on
the other hand, a marked rise in plasma histamine
was observed following verum administration, albeit
without accompanying symptoms.
Methylhistamine in urine
The determination of methylhistamine in urine needs
to be critically examined, since methylhistamine lev-
els depend not only on histamine, but also in general
on the protein content of foods and also rise on a high-
protein but low-histamine diet [19].
There are no objective parameters as yet for
the presence of adverse reactions to ingested
histamine.
Relevance of medications
A number of medications have been deemed to have
a negative effect on histamine-degrading enzymes,
primarily DAO [20, 21]. Medications such as acetyl-
cysteine, metamizole, verapamil, metronidazole, and
metoclopramide have been mentioned [22, 23]. Ac-
cording to a recent literature search, data on these
older reports is inconsistent. More research is needed
to validate the effect of these and other medications
on histamine-degrading enzymes and to identify po-
tential pharmacological interactions in exogenously
absorbed histamine.
The relevance of particular medications with
regard to the degradation capacity of diamine
oxidase needs to be validated in further studies.
Oral provocation with histamine: between
a diagnostic threshold dose and inadvertent
poisoning
The best method to verify an adverse food reaction is
titrated oral provocation, ideally performed in a dou-
ble-blind, placebo-controlled test design that should
have clinical parameters as endpoints. As yet, there
is no established procedure that can be applied in
routine practice for suspected adverse reactions to in-
gested histamine. The specification of an appropri-
ate provocation dose is a prerequisite of diagnosti-
cally valid oral provocation. The ideal dose should
fail to elicit a reaction in a sufficiently large collec-
tive of healthy subjects, while inducing the described
symptoms in subjects suspected to be intolerant. If
unexpected systemic reactions not described in the
patient history are observed, the dose was too high.
The 75-mg dose, which is most frequently selected
in the studies to date, triggered symptoms in 50% of
healthy subjects in one particular study [5]. In an
analysis of patients with atopic dermatitis (AD), sys-
temic reactions were seen in seven patients and four
control subjects following administration of a 75-mg
dose of histamine dihydrochloride (1mg histamine is
equivalent to 1.6mg histamine dihydrochloride) per
kilogram body weight (mg/kg BW). In another study,
administration of a dose of 1.5mg/kg BW elicited re-
actions in 14 AD patients and 11 control subjects [24].
The fact that, in both studies, the provocation doses
triggered reactions in healthy controls prompts the
suspicion of subtoxic effects. It is questionable, there-
fore, whether these doses are suited for diagnostic
purposes in suspected adverse reaction to ingested
histamine.
Recommended approach
Until a validated test system is available, the follow-
ing approaches are proposed for the identification
of symptoms caused by histamine intake (Fig. 2):
In a first step, patients should undergo a three-step




adverse reactions to in-
gestedhistamine
dietary adjustment (Table 2). Titrated provocation
with ascending doses of histamine hydrochloride at
2-h intervals (e. g., 0.5mg/kg BW, 0.75mg/kg BW,
up to 1.0mg/kg BW) could then be considered to
determine the individual’s tolerated dose. Titrated
histamine provocation should be performed under
medical supervision, since systemic reactions ranging
from nausea and vomiting to temporary circulatory
dysregulation may occur. These symptoms are gener-
ally transient and can be managed by administration
of antihistamine agents.
Factors influencing the provocation result
When performing oral provocation tests it must be
borne in mind that individual sensitivity is subject to
considerable variability and numerous concomitant
factors affect intestinal permeability, including the fol-
lowing:
● The use of acetylsalicylic acid, other non-steroidal
anti-inflammatory drugs, as well as other medica-
tions,
● Various, but primarily inflammatory, intestinal dis-
orders,
● Concomitant alcohol use,
● Hormone status,
● Probably also the composition of intestinal flora and
other factors.
Due to a lack of data, it is currently not possible to
propose a suitable histamine dose or an appropriate
procedure for performing oral provocation testing. In
the meantime, titrated provocation tests using esti-
mated individual tolerated doses can yield informa-
tion on the possible presence of impaired histamine
metabolization.
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Table 2 Phasesof the three-stepdietary adjustment
Phase Aim Recommendation Duration
Phase 1:
avoidance
To reduce symptoms to the greatest possible
extent
– Mixed diet with emphasis on vegetables and reduced biogenic amine
intake, in particular histamine intake
– Nutrient optimization
– Changes in meal composition




To expand the choice of food while taking
individual risk factors (stress, menstruation,
medication use, etc.) into account
– Targeted re-introduction of suspected foods while taking the patient’s
individual dietary preferences into consideration
– Determination of individual histamine tolerance
Up to 6 weeks
Phase 3:
long-term diet
Continuous, balanced supply of nutrients
High quality of life
– Individual nutritional recommendations guided by the individual his-
tamine tolerance, taking exogenous risk factors into consideration
–
Variable histamine content in foods
The diagnosis and treatment of adverse reactions
to ingested histamine is hampered by the fact that
the histamine content in food varies significantly de-
pending on maturity, storage time, and processing.
As a result, histamine levels can differ considerably
within the same food product. For example, the his-
tamine content in Emmental cheese varies from <0.1
to 2000mg/kg and in smoked mackerel from <0.1 to
1788mg/kg [25]. These variations make it difficult to
estimate the histamine content of individual meals.
Furthermore, some of the dietary recommenda-
tions that are currently circulating are not supported
by scientific evidence. For example, numerous low-
histamine diets prohibit foods that do not contain
histamine (e. g., yeast), or encourage the avoidance of
so-called “histamine liberators” (pharmacologically
active substances that have a histamine-releasing ef-
fect), despite there being no reliable evidence of their
existence in foods or of their clinical relevance in the
onset of adverse food reactions [26]. The inconsistent
data on biogenic amines in foods make it difficult to
issue safe recommendations on diagnosis and define
treatment measures.
Histamine levels in foods are subject to significant
variation—even within the same food prod-
uct—depending on maturity, storage time, and
particular treatment processes, thereby hampering
diagnosis and medical guidance.
Explanation of terms: adverse reactions to histamine
or histamine intolerance
In summary, it is currently not established whether
an individual sensitivity to ingested histamine is due
to an enzyme defect. The so-called histamine intoler-
ance is more likely a “complex of symptoms that can
be attributed to histamine only in individual cases”
than an isolated clinical picture exclusively triggered
by ingested histamine [27]. That would explain why it
is often not possible to reproduce symptoms follow-
ing small quantities of histamine in the patient history
[27, 28]. It is possible that symptoms only appear in
the presence of concomitant factors (see above). In
this context, an alteration in small intestinal perme-
ability as a prerequisite of symptom onset may be of
relevance. However, the study conducted by Kom-
ericki and coworkers [27, 28] raises the question of
whether symptoms can be affected by orally adminis-
tered histamine at all. The intake of the histamine-de-
grading enzyme DAO was described to reduce symp-
toms irrespective of whether or not histamine was ad-
ministered [28].
We propose favoring the term adverse reaction to
ingested histamine until the underlying pathomecha-
nism for reactions to minute quantities of histamine,
i. e., far below the toxicologically relevant dose, has
been elucidated.
A clarification of the differences between the
terms adverse reaction to ingested histamine and
histamine intolerance is still pending.
Practical approach in daily routine
Even without knowing the underlying pathomech-
anism, patients with suspected an adverse reaction
to ingested histamine can receive helpful advice on
how to alter their dietary habits. In a first step,
however, possible differential diagnoses (see section
“Symptoms and differential diagnoses in patients with
suspected adverse reactions to ingested histamine”)
should be investigated and, where necessary, treated.
If the suspicion of an adverse reaction to ingested
histamine persists, individually relevant quantities of
biogenic amines as well as concomitant factors that
either induce or promote adverse reactions can be
best identified by using a symptom and food diary.
There are several factors capable of increasing the
sensitivity to histamine (see section “Factors influenc-
ing the provocation result”). An increase in symp-
toms is observed in female patients during the pre-
menstrual phase [4]. But dietary factors, such as food
selection, meal composition, and intervals between
meals, can also affect symptoms.
Dietary adjustment
Experience to date (e. g., in the context of individual-
ized nutritional therapy) has shown that tolerance to
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histamine and biogenic amines can be increased by
a three-step dietary adjustment (Table 2). However,
controlled studies are needed to investigate to what
extent nutritional changes are actually able to achieve
biological effects and to affect the natural course of
tolerance. On the other hand controlled studies could
shed light on how strong psychological effects are
achievable by expert advice.
Taking our limited knowledge on the pathomecha-
nism of adverse reactions to ingested histamine into
consideration, the approach described here (Fig. 2) is
recommended in order to avoid generalized, restric-
tive, and long-term low-histamine diets that unneces-
sarily reduce patients’ quality of life.
A diagnostic work-up, combined with individual-
ized nutritional therapy that focuses primarily on
nutrient optimization and helps patients reliably
to differentiate symptoms, is to be preferred over
generalized, restrictive diets.
The value of antihistamine agents
There are no double-blind, placebo-controlled pro-
spective studies on the efficacy of H1 and H2 receptor
blockers in patients with adverse reactions to ingested
histamine. However, themode of action of these drugs
suggests that they ought to work in the treatment of
individual symptoms (e. g., H1 blockers for flushing
and H2 blockers for nausea/vomiting)—at least in the
acute setting (severe dietary errors, e. g., in the context
of festive meals, or scombroid poisoning) [29–31].
In a pragmatic approach, one could conceivably
treat patients with suspected adverse reactions to in-
gested histamine with H1/H2 receptor blockers for
a certain period of time in order to investigate whether
this alters symptoms.
Conclusion and outlook
In summary, the points discussed here show that the
diagnosis of adverse reactions to ingested histamine
has hitherto been made purely on the basis of symp-
toms and in the absence of reliable laboratory pa-
rameters. The treatment approach should be largely
guided by the individual tolerance of affected individ-
uals. Generalized restrictions on food selection are
only relevant for diagnostic purposes and do not help
affected patients in the long term.
More research is needed to establish the relevance
of measuring biomarkers, risk factors in intestinal
function and barrier, as well as the histamine dose
that elicit pharmacological effects of histamine. Until
then, expert nutritional counseling can help patients
to avoid diets that result in an unnecessary reduction
in their quality of life.
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